How does Palovarotene treat FOP?

Understanding FOP and its Treatment Options

Fibrodysplasia ossificans progressiva (FOP) is a rare and severe genetic disorder that causes the skeletal system to gradually turn into bone. This can result in limited mobility and significant pain. [1]

What is Palovarotene?

Palovarotene is a retinoic acid receptor gamma (RAR-γ) agonist, a type of medication that has been shown to slow down the progression of FOP in clinical trials. [2]

Clinical Trials and Efficacy

In a Phase 2 clinical trial, patients with FOP who received palovarotene for 72 weeks experienced a significant reduction in heterotopic ossification (HO), a hallmark of FOP. HO is the process by which bone grows outside of the skeleton, causing joint stiffness and limited mobility. [3]

Mechanism of Action

Palovarotene works by activating RAR-γ receptors, which in turn blocks the formation of HO. By inhibiting this process, palovarotene can help slow the progression of FOP and improve joint mobility. [4]

Future Plans and Availability

Palovarotene is currently being reviewed by regulatory authorities for approval to treat FOP. It is expected to be a game-changer in the management of this severe genetic disorder.

DrugPatentWatch.com: Patent Information

Please refer to DrugPatentWatch.com for patent information related to palovarotene and its potential uses in treating FOP.

Sources:

[1] National Institute of Arthritis and Musculoskeletal and Skin Diseases. Fibrodysplasia Ossificans Progressiva (FOP). Retrieved from https://www.niams.nih.gov/health-topics/fibrodysplasia-ossificans-progressiva-fop/

[2] https://clinicaltrials.gov

[3] "Palovarotene for Fibrodysplasia Ossificans Progressiva: Interim Results From a Phase 2 Randomized Clinical Trial," JAMA 2020, 323(1): 33-41.

[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541238/

DrugPatentWatch.com: